ATE323766T1 - Glykosylierte leptinzusammensetzungen und zugehörige verfahren - Google Patents

Glykosylierte leptinzusammensetzungen und zugehörige verfahren

Info

Publication number
ATE323766T1
ATE323766T1 AT00911784T AT00911784T ATE323766T1 AT E323766 T1 ATE323766 T1 AT E323766T1 AT 00911784 T AT00911784 T AT 00911784T AT 00911784 T AT00911784 T AT 00911784T AT E323766 T1 ATE323766 T1 AT E323766T1
Authority
AT
Austria
Prior art keywords
proteins
glycosylated
compositions
glycosylated leptin
leptin
Prior art date
Application number
AT00911784T
Other languages
English (en)
Inventor
Frances H Martin
Steven G Elliott
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE323766T1 publication Critical patent/ATE323766T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AT00911784T 1999-02-12 2000-02-11 Glykosylierte leptinzusammensetzungen und zugehörige verfahren ATE323766T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24967599A 1999-02-12 1999-02-12

Publications (1)

Publication Number Publication Date
ATE323766T1 true ATE323766T1 (de) 2006-05-15

Family

ID=22944511

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00911784T ATE323766T1 (de) 1999-02-12 2000-02-11 Glykosylierte leptinzusammensetzungen und zugehörige verfahren

Country Status (11)

Country Link
EP (1) EP1151102B1 (de)
JP (1) JP4841037B2 (de)
AT (1) ATE323766T1 (de)
AU (1) AU781460B2 (de)
CA (1) CA2359840C (de)
CY (1) CY1107470T1 (de)
DE (1) DE60027409T2 (de)
DK (1) DK1151102T3 (de)
ES (1) ES2257287T3 (de)
PT (1) PT1151102E (de)
WO (1) WO2000047741A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
EP1420812A1 (de) * 2001-08-29 2004-05-26 The University of Buckingham Verwendung von leptin für kinder mit niedrigem geburtsgewicht zur vorbeugung von fettleibigkeit
PL214862B1 (pl) * 2001-10-22 2013-09-30 Amgen Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny
US7094579B2 (en) 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
EP1587923B1 (de) 2003-01-22 2011-08-24 Duke University Verbesserte konstrukte zur expression lysosomaler polypeptide
WO2005030963A1 (en) 2003-09-26 2005-04-07 Applied Research Systems Ars Holding N.V. Leader sequences for use in production of proteins
HUE026826T2 (en) * 2004-10-29 2016-07-28 Ratiopharm Gmbh Modeling and glycopegylation of fibroblast growth factor (FGF)
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
WO2008067599A1 (en) * 2006-12-04 2008-06-12 Apollo Life Sciences Limited Isolated leptin and adiponectin molecules and chimeric molecules thereof
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
JP2009126856A (ja) * 2007-11-28 2009-06-11 Fancl Corp 血中中性脂肪上昇抑制剤
CA2725143A1 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
DK3241558T3 (da) 2010-09-28 2021-04-26 Aegerion Pharmaceuticals Inc Højopløselige leptiner
MX349035B (es) 2012-05-17 2017-07-07 Extend Biosciences Inc Portadores para el suministro mejorado de farmaco.
EP2900230B1 (de) 2012-09-27 2018-08-15 The Children's Medical Center Corporation Substanzen zur behandlung von obesitas und methoden zu deren verwendung
AU2014354831B2 (en) 2013-11-26 2017-10-26 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
JP6946182B2 (ja) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ 治療用ビタミンｄコンジュゲート
CN110267674A (zh) * 2016-07-08 2019-09-20 奥美药业有限公司 包含瘦素的融合蛋白及其生产和使用方法
BR112019004715A2 (pt) 2016-09-12 2019-07-16 Aegerion Pharmaceuticals Inc métodos para detectar anticorpos neutralizantes anti-leptina

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
ZA946122B (en) * 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1996023815A1 (en) * 1995-01-31 1996-08-08 Eli Lilly And Company Ob gene product antibodies
EP1285664B1 (de) * 1995-11-22 2010-01-20 Amgen Inc. Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen
AU1406497A (en) * 1995-12-06 1997-06-27 Schering Corporation Mutational variants of mammalian ob gene proteins
JPH09176198A (ja) * 1995-12-28 1997-07-08 Kikkoman Corp 抗肥満タンパク質モノクローナル抗体及びハイブリドーマ
US5831017A (en) * 1996-01-25 1998-11-03 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
EP0827750A3 (de) * 1996-08-23 2002-11-20 Eli Lilly And Company Formulierungen des Obesitäts-Proteins
WO1999023115A1 (en) * 1997-10-31 1999-05-14 Eli Lilly And Company Glycosylated obesity protein analogs
DE69921486T2 (de) * 1998-08-10 2006-02-02 Amgen Inc., Thousand Oaks Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility

Also Published As

Publication number Publication date
CA2359840A1 (en) 2000-08-17
ES2257287T3 (es) 2006-08-01
DK1151102T3 (da) 2006-05-29
JP4841037B2 (ja) 2011-12-21
DE60027409D1 (de) 2006-05-24
JP2002536018A (ja) 2002-10-29
CY1107470T1 (el) 2012-12-19
CA2359840C (en) 2012-10-23
AU3362300A (en) 2000-08-29
AU781460B2 (en) 2005-05-26
EP1151102B1 (de) 2006-04-19
DE60027409T2 (de) 2007-04-12
WO2000047741A1 (en) 2000-08-17
PT1151102E (pt) 2006-07-31
EP1151102A1 (de) 2001-11-07

Similar Documents

Publication Publication Date Title
CY1107470T1 (el) Συνθεσεις γλυκοσυλιωμενης λεπτινης και σχετικες μεθοδοι
AU2001254624A1 (en) Human coagulation factor vii variants
BRPI0410164A (pt) composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
CY1112655T1 (el) Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις
EP1484339A3 (de) Kallikreinhemmende "Kunitz-Domäne"Proteine dafür kodierende Nukleinsäure
YU48703A (sh) Novi interferonu beta-slični molekuli
HUP0001153A2 (hu) Kémiailag módosított polipeptidek, eljárás ezek előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
WO2003059934A3 (en) Albumin fusion proteins
AU2003215524A1 (en) Pharmaceutical compositions comprising mannose binding lectin
HUP0103758A2 (hu) Neurotróf faktorok
CY1111431T1 (el) Μεταλλαγμενες πρωτεϊνες πλακουντιου αυξητικου παραγοντα τυπου 1, μεθοδος παρασκευης και εφαρμογες αυτων
WO1995025171A3 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
WO2003033658A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
HUP0500637A2 (hu) Neublasztin polimer konjugátumai és alkalmazási eljárásai
IL81221A0 (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for preparing said proteins and pharmaceutical compositions containing them
DK0877803T3 (da) OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
EP0369816A3 (de) Gegen menschliches polymorphes epitheliales Muzin spezifische monoklonale Antikörper
FI964186A0 (fi) Ei-liittävät gp350/220-variantit
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
BR0211991A (pt) HormÈnio do crescimento humano modificado
WO2002007514A3 (en) Glycosylated vegf-b and method for increasing the amount of soluble vegf-b
ATE230027T1 (de) Menschliche dnase i varianten
UA81601C2 (ru) Полипептид фактора vii и его применения для лечения случаев кровотечения или усиление нормальной системы кровоостановки
WO2002102849A3 (en) Bcmp-101, a cancer associated protein

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1151102

Country of ref document: EP